China Acts Quickly In Latest Drug-Related Death Case
This article was originally published in PharmAsia News
Executive Summary
China's regulators appear to be serious about cracking down on unsafe drugs in the country as they respond to the six recent hospital deaths. Unlike previous incidents when fake or adulterated drugs were found, the government has moved swiftly in the hospital case involving a single batch of human immunoglobin. But the drug-making industry in China remains highly fragmented, a situation that hampers any efforts of officials to control the safety of medicines. (Click here for more